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ABSTRACT Tomaymycin reacts covalently with guanine in the DNA minor groove, exhibiting considerable specificity for the
flanking bases. The sequence dependence of tomaymycin bonding to DNA was investigated in synthetic DNA oligomers and
polymers. The maximum extent of bonding to DNA is greater for homopurine and natural DNA sequences than for alternating
purine-pyrimidine sequences. Saturation of DNA with tomaymycin has little effect on the melting temperature in the absence
of unbound drug. Fluorescence lifetimes were measured for DNA adducts at seven of the ten unique trinucleotide bonding
sites. Most of the adducts had two fluorescence lifetimes, representing two of the four possible binding modes. The lifetimes
cluster around 2-3 ns and 5-7 ns; the longer lifetime is the major component for most bonding sites. The two lifetime classes
were assigned to R and S diastereomeric adducts by comparison with previous NMR results for oligomer adducts. The
lifetime difference between binding modes is interpreted in terms of an anomeric effect on the excited-state proton transfer
reaction that quenches tomaymycin fluorescence. Bonding kinetics of polymer adducts were monitored by fluorescence
lifetime measurements. Rates of adduct formation vary by two orders of magnitude with poly(dA-dG)-poly(dC-dT), reacting
the fastest at 4 x 10-2 M-1 s-1. The sequence specificity of tomaymycin is discussed in light of these findings and other
reports in the literature.
INTRODUCTION
Tomaymycin is a member of the pyrrolo[1,4]benzo-
diazepine group of antitumor antibiotics, which includes
anthramycin, sibiromycin, and the neothramycins A and B.
These antibiotics react with guanine bases in the minor
groove of B-form DNA (Hurley and Needham-
VanDevanter, 1986). The aminal linkage between the drug
ClI and guanine N2 was suggested by structure-activity
relationships and model building (Petrusek et al., 1981) and
confirmed by 'H NMR in a bis-tomaymycin-d(CICGAAT-
TCICG)2 adduct (Boyd et al., 1990b). Formation of the
DNA adduct appears to proceed by a SN1 mechanism
through the N10-Cl 1 imine intermediate (Fig. 1). Conse-
quently, the configuration at C I1 of the carbinolamine does
not influence the stereochemical outcome of the nucleo-
philic attack (Barkley et al., 1986). Four binding modes are
possible: R or S configuration at ClI with the aromatic ring
of the drug pointing toward the 3' or 5' end of the co-
valently attached DNA strand (Fig. 2). Molecular modeling
shows that the minor groove can accommodate all four
binding modes of tomaymycin and anthramycin with min-
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imal distortion of the helix (Rao et al., 1986; Remers et al.,
1986; Cheatham et al., 1988; Boyd et al., 1990b; Barkley et
al., 1991; Remers et al., 1992).
The pyrrolo[1,4]benzodiazepines have remarkable se-
quence specificity for such small molecules. In addition to
specific reaction with guanine, the drugs exhibit preferences
for the flanking bases. Chemical footprinting with MPE-
Fe(II) and 1, 10-phenanthroline-copper showed protection of
3-5-base pair sequences on DNA (Hertzberg et al., 1986;
Pierce et al., 1993). The sequence preference of tomaymy-
cin and anthramycin has been determined by exonuclease
III digestion, A exonuclease digestion, and UvrABC nucle-
ase incision assays (Hurley et al., 1988; Pierce et al., 1993).
The relative reactivity of all 16 possible trinucleotide bond-
ing sites 5'NGN was quantified by UvrABC nuclease inci-
sion analysis (Pierce et al., 1993). Although 5'AGA is the
preferred bonding site for both drugs, the sequence speci-
ficities of tomaymycin and anthramycin are different.
Tomaymycin clearly exhibits the highest bonding at the
5'AGA sequence, whereas anthramycin reacts almost as
well at 5'AGG sites. Both drugs react strongly at 5'AGC
and 5'GGA sites; tomaymycin also reacts strongly at
5'GGC and 5'TGC. However, the extent of DNA modifi-
cation by tomaymycin is less than that by anthramycin at the
same drug concentration in the assay. The sequence speci-
ficity of the pyrrolo[1,4]benzodiazepines has been proposed
to be due to sequence-dependent variations in local DNA
structure and flexibility. The x-ray structure of anthramycin
bonded to d(CCAACGTTGG)2, which contains two 5'TGG
sites, shows a low twist angle for the T-G and G-G steps in
the bonding site (Kopka et al., 1994). The low average twist
of purine-purine steps in DNA would provide a good fit for
the drug and explain the 5'RGR sequence preference of
anthramycin. Correlation of the sequence preferences of
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FIGURE 1 Proposed mechanism for the reaction of tomaymycin with
DNA.
anthramycin and tomaymycin with reaction rates and DNA
bending suggests that DNA flexibility also contributes to
the sequence specificity (Kizu et al., 1993).
The binding modes of tomaymycin at two sequences on
duplex oligomers have been deduced from high-field NMR,
molecular modeling, and fluorescence lifetime data. In the
d(CICGAATTCICG)2 adduct, which contains two 5'CGA
sites, tomaymycin bonds with S configuration and 3' orien-
tation of the aromatic ring (Boyd et al., 1990b). However,
two types of adducts are formed at the 5'TGC site in
d(ATGCAT)2, which were tentatively identified as the I iS
and IR diastereomers with 3' and 5' orientations, respec-
tively (Cheatham et al., 1988). The relative placement of
two sites has also been examined by NMR and molecular
modeling as a prelude to the design of an interstrand cross-
linking agent (Bose et al., 1992; Wang et al., 1992). Tomay-
mycin forms S3' adducts at the 5'CGA and 5'AGC sites in
d(CICGATCICG)2 and d(CIAGCICTCG)2, respectively. It
appears to form at least two types of adduct in d(CITCIC-
GACG)2, presumably because of juxtaposition of the two
5'CGA sites (Wang et al., 1992). Anthramycin forms S3'
adducts at the 5'TGC site in d(ATGCAT)2 (Boyd et al.,
1990a) and the 5'TGG sites in d(CCAACGTTGG)2 (Kopka
et al., 1994).
Previously we showed that the llS and 1 R diaste-
reomers of tomaymycin have different fluorescence life-
times and slightly different absorption spectra in solution
and presumably also in DNA adducts (Barkley et al., 1986).
This paper presents fluorescence studies of the sequence
dependence of tomaymycin bonding to DNA. The maxi-
mum extent of reaction with various synthetic DNA poly-
mers is determined by a steady-state fluorescence assay.
The fluorescence lifetimes of the polymer adducts are in-
terpreted by comparison with results for oligomer adducts.
Finally, the rates of formation for different polymer adducts
are measured by time-resolved fluorescence techniques.
MATERIALS AND METHODS
Chemicals
Tomaymycin 11-methyl ether was a generous gift from Dr. M. Kohsaka
(Fujisawa Pharmaceutical Co., Osaka, Japan). The buffer was 0.01 M
phosphate, 0.1 M NaCl, 0.1 mM EDTA at the indicated pH. Synthetic
FIGURE 2 Four possible binding modes of tomaymycin.
polydeoxynucleotides (Pharmacia) were dissolved in pH 7.5 buffer. Calf
thymus DNA (Sigma type I) was purified by phenol extraction and was
dialyzed into pH 7.5 buffer. Nucleotide concentration was determined from
the absorbance at 260 nm using the following extinction coefficients
(Inman and Baldwin, 1962; Morgan and Wells, 1968; Wells et al., 1970):
poly(dG).poly(dC), 7400 M-' cm-'; poly(dA-dG).poly(dC-dT), 5700
M-l cm-'; poly(dG-dT).poly(dA-dC), 6500 M-l cm- '; poly(dG-
dC)poly(dG-dC), 8400 M-l cm-; poly(dG-m5dC).poly(dG-m5dC), 8400
M- cm- ; calf thymus DNA, 6800 M- cm- '. Oligodeoxynucleotide
duplexes were provided by Dr. L. H. Hurley and were synthesized and
purified as described elsewhere (Cheatham et al., 1988; Boyd et al., 1990b;
Wang et al., 1992). The lyophylized samples were reconstituted with
distilled water and diluted into pH 7.0 buffer or were dissolved in pH 7.0
buffer. Duplex concentration was estimated from the absorbance at 260 nm
using calculated extinction coefficients as described before (Cheatham et
al., 1988; Boyd et al., 1990b).
Preparation of adducts
Stock solutions of tomaymycin 11-methyl ether were prepared in methanol
and were stored at -20'C. The concentration of the stock solution was
determined from the absorbance at 320 nm using an extinction coefficient
of 3600 M- 1 cm-1 (Arima et al., 1972). An aliquot of the stock solution
was placed in a vial, and the methanol was evaporated by a stream of N2.
Polynucleotide solution (1 X 10-3 M nucleotide) was added to give P/D =
100. d(AAGCTT)2 and d(ATGCAT)2 solutions containing 3 x 10-4 M
duplex were added to give one duplex per drug. The reaction was allowed
to equilibrate overnight at room temperature and then 1-2 weeks at 4°C,
depending on the DNA. d(CICGATCICG)2, d(CIAGCICTCG)2, d(CIT-
CICGACG)2, and d(CICGAATTCICG)2 adducts were provided as lyo-
phylized samples with 0.5 duplex/drug, respectively, and were diluted to
1-3 X 10-5 M duplex. (The concentration units of d(CICGAATTCICG)2
adduct for fluorescence experiments in Boyd et al. (1990b) were nucleo-
tides.) Solutions of DNA adducts appeared to be stable for at least 1 year
when stored in the refrigerator.
Unreacted tomaymycin was removed by solvent extraction or by dial-
ysis. Solutions of polynucleotide and calf thymus DNA adducts were
extracted three or four times with an equal volume of cold, pH 7.5
buffer-saturated 2-butanol or ethyl acetate to remove free drug and two or
three times with an equal volume of ether to remove 2-butanol. The ether
was evaporated by bubbling N2 through the solution. Traces of ethyl
acetate were removed under vacuum. Oligonucleotide adducts were ex-
tracted similarly with pH 7.0 buffer-saturated ethyl acetate. Aliquots (1-1.5
ml) of solutions of polynucleotide and calf thymus DNA adducts were
dialyzed against three 500-ml volumes of pH 7.5 buffer for 48 h at 4°C.
Photobleaching under laser light was completely eliminated by scrupulous
removal of 02 as described before (Chen et al., 1994). Solutions for
thermal denaturation experiments were overlaid with silicon oil. Absor-
bance at 260 nm was measured as a function of temperature in an Aviv
118DS spectrometer equipped with a thermoelectric cell holder.
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Saturation binding was determined by a difference method, in which the
amount of unbound tomaymycin was measured by fluorescence after
2-butanol extraction. Solutions of polynucleotide and calf thymus DNA
adducts (2.5 X 10-4 M nucleotide, P/D = 5) in pH 7.5 buffer were
equilibrated overnight at 25°C and then for 6 days at 4°C or for a second
day at 25°C. A 2.1-ml volume of adduct solution and three 2.1-ml volumes
of 5 x 10-5 M tomaymycin in pH 7.5 buffer were extracted three times
with 5-ml volumes of pH 7.5 buffer-saturated 2-butanol at 4 or 25°C. After
each extraction 4 ml of the 2-butanol phase was drawn off and the aqueous
phase was extracted with ether. The fluorescence intensity of the 2-butanol
phase was recorded at 337 nm excitation wavelength, 420 nm emission
wavelength as described before (Barkley et al., 1991). The error in fluo-
rescence intensity was <1.4% for the 2-butanol phases from the three
tomaymycin samples in buffer. Usually >95% of the free tomaymycin was
removed in the first extraction.
Fluorescence lifetime measurements
Adduct solutions were placed in 4 X 10 mm2 stoppered cells. The absor-
bance at 330 nm with 4-mm path length was <0.15. Fluorescence lifetimes
were measured at 5C on a Photochemical Research Associates time-
correlated single photon counting instrument equipped with a picosecond
dye laser excitation source as described before (Chen et al., 1994). A
thermoelectrically cooled Hamamatsu R2809U microchannel plate photo-
multiplier was used in a few experiments. Some of the lifetime measure-
ments were made using flash lamp excitation and a T optical design. The
flash lamp was filled with 1.7 atm of N2 and operated at 20-25 kHz with
5 kV applied across a 1.5-mm electrode gap. Under these conditions the
pulse width was about 1.7 ns FWHM. Excitation wavelengths were se-
lected by interference filters (10-nm bandpass): 313 and 337 nm (micro-
Coatings; Westford, MA) and 355 nm (Corion 3500 or 3600; Holliston,
MA). Because the flash lamp excitation was unpolarized, a single polarizer
oriented at 35°C was used on the emission side to eliminate anisotropic
effects. Emission wavelengths were selected by Instruments SA H-10
monochromators (8-nm bandpass). The sample temperature was controlled
by a circulating water bath.
Fluorescence decays from a sample and a reference fluorophore or lamp
profile were acquired contemporaneously. Peak counts were 2.5 x 104
with laser excitation and 1-2 x 104 with the flash lamp. Counting rates
were < 1% of the laser excitation rate and <2% of the flash lamp excitation
rate. Decay curves were stored in 512 channels of 0.06 or 0.108 ns/channel
or in 1024 channels of 0.03 or 0.04 ns/channel. Solutions of POPOP
(Fluka) in 75% ethanol and 0.8 M KI (containing a trace of sodium
thiosulfate to retard 13 formation) or BBO in ethanol were used as
reference fluorophore. Lifetimes of 0.21-0.32 ns for quenched POPOP and
1.28 ns for BBO were determined in separate experiments using anthracene
in ethanol as the monoexponential standard. Scattering from an aqueous
solution of glycogen was used for the lamp profile in experiments on poly
dGC adduct with laser excitation and microchannel plate detection.
Fluorescence decay data were fitted by reference deconvolution to a
sum of exponentials (Kolber and Barkley, 1986),
'(AexAe ;em )exp(- tIT), (1)
where ai(Xex Aem) is the amplitude at excitation and emission wavelengths,
Aex and Aem, andTi is the fluorescence lifetime for component i. Goodness
of fit was judged from the value of reduced chi-square X, and the shape of
the autocorrelation function of the weighted residuals. The reference life-
time was an adjustable parameter in analyses of the monoexponential
standard. Its value was fixed in analyses of tomaymycin decays. Decay
data deconvolved with a lamp profile used Eq. 1 as the fitting function.
Fluorescence decay curves acquired for multiple samples at different
excitation and emission wavelengths were deconvolved by single-curve
analysis and by global analysis. The global analysis program assumes that
the lifetimes but not the amplitudes are independent of sample treatment
and wavelength (Knutson et al., 1983).
Bonding kinetics
The rate of formation of DNA adduct was monitored by fluorescence
lifetime measurements using flash lamp excitation. An aliquot of tomay-
mycin methyl ether stock solution was placed in a cell, the methanol was
evaporated, and polynucleotide solution (1 10-3 M nucleotide) was
added to give P/D = 100. After vortexing, the cell was placed in the sample
holder. Initially 30 consecutive decay curves with at least 2 x 103 peak
counts were acquired at 313 nm excitation wavelength, 420 nm emission
wavelength. Another 20-50 decay curves with 1 104 peak counts were
acquired at longer times up to 1-2 weeks until there was no further change
in the relative amplitude of the free drug component.
The complete set of decay curves was fitted to two or three exponentials
by global analysis. Rate constants were determined from changes in rela-
tive amplitudes of the lifetime components as a function of time as
described before (Chen et al., 1994). Because the reaction
k
TOM + DNA -, TOM - DNA (2)
was carried out with a 25- to 50-fold excess of potential DNA bonding
sites, pseudo-first-order kinetics were assumed at early times. The pseudo-
first-order rate constant k' = k[DNA]. was determined from the slope of
the linear portion of a plot of -ln af versus t, where af is the relative
amplitude of the free drug decay. For a single species of DNA adduct, the
rate of disappearance of free drug equals the rate of formation of drug-
DNA adduct. For two species of DNA adduct formed by two concurrent
reactions like Eq. 2, the rate of disappearance of free drug equals the sum
of the rates of formation of the two adducts: k' = k' + k2. The pseudo-
first-order rate constant ki for species i is obtained from
ai = kj'k'[l- exp( - k't)]. (3)
The rate constants k' and k2 were evaluated by two methods with equiv-
alent results: 1) k' and the amplitude ratio a1/a2 at equilibrium and 2)
nonlinear fits of the amplitude data for the major lifetime component to Eq.
3. Nonlinear fits of the amplitude data for the minor component gave less
satisfactory results.
RESULTS
Synthetic DNA adducts
The absorption and fluorescence emission spectra of tomay-
mycin bonded to guanine-containing synthetic DNA poly-
mers are similar to the spectra of the calf thymus DNA
adduct (Barkley et al., 1991). Table 1 lists the absorption
and emission maxima of the synthetic DNA adducts.
TABLE I Properties of tomaymycin-polynucleotide adducts
Amax Amax Saturation ratio*
Polynucleotide (nm) (nm) (nucleotide/drug)
Poly(dG) * poly(dC) 329 406 17.4 (25.8)
Poly(dA-dG) * poly(dC-dT) 327 410 18.4 (17.9)
Poly(dG-dT) - poly(dA-dC) 327 407 27.8 (41.0)
Poly(dG-dC) *poly(dG-dC) 329 409 28.2 (39.6)
Poly(dG-m5dC) * poly(dG-m5dC)t 326 413 42.6 (120.8)
Calf thymus DNA 330 407 17.2 (18.7)
pH 7.5, 5°C, [P] = 1 X 10-3 M. Absorption and emission spectra were
measured on samples with P/D = 100. Free drug was removed by extrac-
tion or dialysis.
*Amount of drug bonded at saturation was determined as described in
Materials and Methods. Data for 25°C in parentheses.
tFree drug was not removed before measuring spectra.
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The maximum extent of bonding to synthetic DNA poly-
mers was measured at 5 and 25°C by a fluorescence assay.
Assuming the drug molecule covers a minimum of three
base pairs and every base pair begins a potential bonding
site, the DNA would saturate at three base pairs per drug or
P/D = 6. The synthetic DNA polymers were reacted with
excess tomaymycin at P/D = 5. Unreacted drug was re-
moved by extraction and quantified by fluorescence. The
fraction of tomaymycin bonded to DNA was determined by
comparison of identical samples with and without DNA. A
nucleotide-to-drug ratio of 18.7 was obtained for calf thy-
mus DNA at pH 7.5, 25°C. This compares to a value of 18.2
determined by radiometric assay at pH 7.2, 22°C (Hurley et
al., 1977). Table 1 gives the results for five synthetic DNA
polymers. At 5°C the two homopurine sequences, poly dG
and poly dAG, bond tomaymycin to the same extent as calf
thymus DNA: 18 nucleotides per drug. The copolymer
sequences poly dGC and poly dGT saturate at 28 nucleo-
tides per drug, whereas the methylated sequence poly
dGm5C saturates at 42 nucleotides per drug. The saturation
ratios are larger at 25°C, except in the case of poly dAG and
calf thymus DNA.
The melting temperatures of synthetic DNA polymers
saturated with tomaymycin were also determined. After
extraction of free drug, the adduct solutions were diluted
eightfold with water to give a final [Na+] = 14.5 mM. The
bound tomaymycin increased the Tm of poly dG, poly dAG,
poly dGT, and calf thymus DNA by about 10. The Tm of
poly dGC and poly dGm5C was >1000C with and without
antibiotic. Previously, Nishioka et al. (1972) reported a 130
increase in the melting temperature of Escherichia coli
DNA measured in the presence of a 40-fold excess of
tomaymycin over the saturation ratio (P/D = 0.44). The Tm
of calf thymus DNA increased by only 90 for a ninefold
excess of tomaymycin over the saturation ratio (P/D = 2).
Apparently the presence of unreacted antibiotic stabilizes
the DNA helix against thermal denaturation.
Lifetimes of polymer adducts
Fluorescence decays of synthetic DNA adducts were ac-
quired at various excitation and emission wavelengths.
Measurements were made at 5°C on samples equilibrated at
P/D = 100 before and after solvent extraction or dialysis to
remove free tomaymycin. The decay curves were decon-
volved in single-curve and multiple-curve analyses. Decay
curves for each synthetic DNA under different experimental
conditions plus a free tomaymycin decay curve were ana-
lyzed globally with the lifetimes linked. Table 2 presents the
results of global analyses of one or more samples. Only
relative amplitudes and lifetimes for the DNA adducts are
given. At 5°C the lifetime of free tomaymycin was 1.1 ns.
The amount of unreacted tomaymycin at equilibrium was
estimated from the amplitude of the 1.1 ns decay. In a
mixture of fluorophores the relative amplitude of compo-
TABLE 2 Fluorescence lifetime data for tomaymycin-
polynucleotide adducts
Aex T1 T2
Polynucleotide (nm) a, (ns) (ns) X:
Poly(dG) - poly(dC)* 1.00 7.2 1.4
Poly(dA-dG) * poly(dC-dT)M 333 0.63 ± 0.05 7.2 4.8 1.6
Poly(dG-dT) * poly(dA-dC)§ 313 0.83 ± 0.02 5.3 3.1 1.2
337 0.88 ± 0.02
355 0.93 ± 0.01
Poly(dG-dC) poly(dG-dC)Q 332 0.82 ± 0.01 7.5 4.6 1.8
Poly(dG-m5dC)* poly(dG-m5dC) 1 313 0.88 ± 0.03 7.6 4.7 1.0
337 0.90 ± 0.01
355 0.94 ± 0.01
pH 7.5, 5°C, [P] = 1 X 10-3 M, P/D = 100. Global analysis of data
acquired at the indicated A,, and Acm = 400-420 nm (5- or 10-nm
intervals).
*Three samples: equilibrated, extracted, and dialyzed. Results from fit to
two exponentials with free drug component subtracted.
tExtracted sample. Results from fit to four exponentials with free drug
component (1.04 ns) and stray laser light (30 ps) subtracted.
tFour samples: equilibrated for 2 and 6 weeks, extracted, and dialyzed.
Results from fit to three exponentials with free drug component subtracted.
qExtracted sample. Results from fit to four exponentials with free drug
component (1.05 ns) and stray laser light (45 ps) subtracted.
IlFour equilibrated samples. Results from fit to three exponentials with free
drug component subtracted.
nent i is
Cii(Aex, Aem) = Ei(Aex)Ii(Aem)kriCi, (4)
where Ei(Aex) is the molar extinction coefficient, Ii(Aem) is
the fluorescence emission spectrum, kr, i is the radiative rate,
and ci is the concentration. The emission spectra and radi-
ative rates are almost the same for free and bound tomay-
mycin, and their relative absorbance (free/bound) is about
1.5 at 313 nm and 0.42 at 337 nm (Barkley et al., 1991). In
equilibrated samples with P/D = 100 at 5°C the fraction of
free drug was roughly 20% for poly dG and poly dGm5C,
but only 10% for poly dAG, poly dGT, and poly dGC.
The poly dG adduct has a single fluorescence lifetime of
7.2 ns. The fluorescence decays were best fit by double
exponentials in single- and multiple-curve analyses. One
component had a lifetime of 1.15-1.18 ns, greater amplitude
at 313 nm excitation wavelength than at 337 or 355 nm, and
smaller amplitude in extracted or dialyzed samples com-
pared to equilibrated samples. This component was as-
signed to free tomaymycin.
The other polynucleotide adducts have two fluorescence
lifetimes: 7.2 and 4.8 ns for poly dAG, 5.3 and 3.1 ns for
poly dGT, 7.5 and 4.6 ns for poly dGC, and 7.6 and 4.7 ns
for poly dGm5C. Although it was difficult to resolve the
closely spaced biexponential decay of these DNA adducts in
the presence of small amounts of free tomaymycin, there
was clear evidence for two species of DNA adduct. For
example, in the case of poly dGC adduct (Fig. 3), the
fluorescence decays of extracted sample gave poor fits to a
single exponential with Xr2 = 29 and a lifetime of 6.6 ns.
Double exponential fits of these data gave a Xr2 value of 6.9
with lifetimes of 6.9 and 0.5 ns. It was possible to resolve a
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FIGURE 3 Fluorescence decay of tomaymycin-poly dGC adduct. Aex =
332 nm, Aem = 400 nm, 0.040 ns/channel. pH 7.5, 5°C, [P] = 1 10-3
M, P/D = 100, extracted sample. Results from global analysis of data
acquired at Aex = 332 nm and Aem = 400-420 nm (5-nm intervals),
including a decay curve for tomaymycin. Sharp spike is lamp profile.
Noisy curve is sample decay; smooth curve is best fit to (top) three
exponentials, a, = 0.36, T, = 7.04 ns, a2 = 0.12, T2 = 1.05 ns, a3 = 0.53,
T3 = 0.035 ns; global Xi = 2.8, and (bottom) four exponentials, a1 = 0.28,
T, = 7.52 ns, a2 = 0.11, T2 = 4.58 ns, a3 = 0.08, T3 = 1.05 ns, a4 = 0.52,
T4 = 0.045 ns; global Xi = 1.8. Weighted percentage residuals and
autocorrelation function of the residuals (inset) are also shown.
triple exponential with one lifetime corresponding to free
drug by including a tomaymycin decay curve in the global
analysis. A four exponential fit improved the xr2 value to 1.8
and resolved a minor species of poly dGC adduct along with
a 30-50-ps component for stray laser light. The longer
lifetime component constitutes the major species of these
polynucleotide adducts. As seen in Table 2, the relative
amplitude of the major component is independent of emis-
sion wavelength, so the emission spectra of the two species
are the same. However, the amplitude of the major compo-
nent increases with excitation wavelength in poly dGT and
poly dGm5C adducts. This shows that the absorption spectra
of the two species are different, with the major component
absorbing slightly to the red of the minor component.
Lifetimes of oligomer adducts
Table 3 lists the fluorescence decay parameters of six oli-
gomer duplex adducts. In the hexamer sequences, bonding
at guanine on one strand blocks the site on the other strand,
so that only one drug molecule bonds per duplex. In the
decamer and dodecamer sequences, the two sites are far
enough apart to fit two drug molecules per duplex, one at
the internal guanine on each strand. Terminal guanine is not
a bonding site. The hexamers AAGCTT and ATGCAT
form two species of adduct. In the AAGCTT adduct, the
longer lifetime component is the major species and the
absorption spectra of the two components are almost iden-
tical. However, in the ATGCAT adduct, the two lifetime
components are present in roughly equal amounts and the
spectrum of the 5.7-ns component is blueshifted relative to
the 2.3-ns component. Two binding modes were observed
by NMR for ATGCAT and assigned to S3' and R5' adducts,
although the population of the two diastereomers was not
deduced (Cheatham et al., 1988).
One decamer sequence, CICGATCICG, forms a single
adduct with a 5.6-ns lifetime. NMR also showed a single
TABLE 3 Fluorescence lifetime data for tomaymycin-
oligonucleotide adducts
Aex T 2
Oligonucleotide (nm) a1 (ns) (ns) Xr2
d(AAGCTJ7)2* 313 0.70 ± 0.01 5.1 2.9 1.2
337 0.70 ± 0.03
355 0.64 ± 0.01
d(ATGCAT)2t 313 0.60 ± 0.02 5.7 2.3 1.1
337 0.51 ± 0.02
355 0.36 ± 0.01
d(CICGATCICG)2' 1.00 5.6 1.3
d(CIAGCICTCG)2q 318 0.89 ± 0.01 5.4 2.6 1.35
323 0.95 ± 0.01
328 0.96 ± 0.01
333 0.99 ± 0.01
d(CITCICGACG)2' 318 0.640 ± 0.003 5.6 1.4 1.3
323 0.726 ± 0.002
328 0.796 ± 0.003
333 0.825 ± 0.005
d(CICGAATTCICG)211 1.0 6.4 1.09
313 0.917 ± 0.002 6.5 2.9 1.05
337 0.94 ± 0.01
355 0.964 ± 0.006
pH 7.0, 5°C. Global analysis of data acquired at indicated Aex and A,m.
*Aem = 410, 420, and 430 nm. Two samples: extracted and 10-fold dilution
of extracted sample equilibrated for 24 h. Results from fit to three expo-
nentials with free drug component subtracted. Amplitudes are mean values
from extracted sample.
tAem = 410 and 420 nm. Extracted sample. Results from fit to three
exponentials with free drug component subtracted.
§Aex = 313, 323, 328, and 333 nm; Aem = 395-415 nm (5-nm intervals).
Extracted sample.
1Aem = 395-415 nm (5-nm intervals). Extracted sample.
IIAem = 400-440 nm (10-nm intervals). Seven samples: equilibrated for 4
weeks, threefold dilution before and after extraction, and 6-, 12-, 24-, and
48-fold serial dilutions of extracted sample equilibrated for 24 h after each
dilution. Results from fits to two and three exponentials with free drug
component subtracted. Amplitudes are mean values from threefold diluted
sample before and after extraction.
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species of adduct with S3' binding mode (Wang et al.,
1992). The other decamers, CIAGCICTCG and CITCIC-
GACG, form two species of adduct. The major component
has a lifetime of 5.4-5.6 ns and a redshifted absorption
spectrum. For the CIAGCICTCG adduct, NMR showed a
single S3' binding mode (Wang et al., 1992). Presumably,
the amount of minor lifetime component present is too low
(<10%) to detect by NMR. However, for the CITCIC-
GACG adduct, NMR indicated more than one binding
mode, at least one of which has S configuration (Wang et
al., 1992). The observation of multiple binding modes in the
CITCICGACG sequence was attributed to the proximity of
the two 5'CGA bonding sites. The dodecamer sequence
CICGAATTCICG appears to form a single species of ad-
duct with a 6.4-ns lifetime. Global analysis of data for
equilibrated, extracted, and diluted samples plus free tomay-
mycin gave an excellent fit to a double exponential with a
free drug lifetime of 1.18 ns. Although it was possible to
resolve a triple exponential with a 1.18-ns lifetime for the
free drug, the evidence for a minor 2.9-ns component is
weak. There is no improvement in the global Xr2 or auto-
correlation function between the double and triple exponen-
tial fits. Moreover, the amplitude of the 1. 18-ns decay in the
triple exponential fit does not show the excitation wave-
length dependence characteristic of free tomaymycin. A
single S3' binding mode for CICGAATTCICG adduct was
observed by NMR (Boyd et al., 1990b).
Table 4 summarizes the lifetime data for the synthetic
polymer and oligomer adducts. The bonding sequences in-
clude seven of the ten unique of 16 possible trinucleotide
sites on natural DNA. The lifetimes span a 6-ns range from
1.4 to 7.6 ns, with clusters around 2-3 ns and 5-7 ns. NMR
identifies the 5.6- and 6.4-ns lifetimes of the 5'CGA bond-
ing sites as the 53' binding mode. This suggests that the
5-7-ns lifetime group represents S3' adduct and assigns the
5.7-ns lifetime of the 5'TGC site to the S3' binding mode
and the 2.3-ns lifetime to the R5' binding mode. We argue
that the 2-3-ns lifetime group represents R5' adduct.
Bonding kinetics
Fluorescence lifetime data were acquired at 313 nm excita-
tion wavelength and 420 nm emission wavelength as a
TABLE 4 Tomaymycin lifetimes at 5'NGN bonding sites
Bonding sequence T, (ns) T2 (ns) Context
GGG 7.2 Polymer
AGA 7.2 4.8 Polymer
AGC 5.1 2.9 Hexamer
5.4 2.6 Decamer
CGA 5.6 Decamer
5.6 1.4 Decamer
6.4 Dodecamer
TGC 5.7 2.3 Hexamer
TGT 5.3 3.1 Polymer
CGC 7.5 4.6 Polymer
m5CGm5C 7.6 4.7 Polymer
Data from Tables 2 and 3.
function of time after mixing tomaymycin and synthetic
DNA polymer. The decay curves from the kinetics experi-
ment were deconvolved simultaneously with a free tomay-
mycin decay curve. Fig. 4 depicts the time course of the
relative amplitudes of the free drug decay and the two
lifetime components of the poly dGC adduct. The amplitude
of each species is proportional to its concentration. The rate
constants for formation of DNA adducts were calculated
assuming pseudo-first-order kinetics. Table 5 gives the
pseudo-first-order rate constants measured at 1 X 10-3 M
nucleotide as well as bimolecular rate constants estimated
using the guanine nucleotide concentration. The rates of
adduct formation are slow and vary by two orders of mag-
nitude among adducts. Poly dAG reacts the fastest, with an
overall bimolecular rate constant of 4 X 10-2 M- I s- . The
minor species of the poly dGC and poly dGm5C adducts are
the slowest to form, with rate constants of 2-4 X 10-4 M- I
s'-. The reaction of pyrrolo[1,4]benzodiazepines with DNA
is acid catalyzed, and the rate is proportional to hydrogen
ion concentration (Kohn et al., 1970, 1974). Decreasing the
pH from 7.5 to 5.5 increases the rate about 100-fold. Ac-
cording to the proposed mechanism (Fig. 1), the acid-
catalyzed step is formation of the imine intermediate. The
imine is nonfluorescent. Presumably, the overall reaction
involves association of the imine with DNA followed by
covalent reaction. However, noncovalent bonding of the
drug to DNA would not be detected by fluorescence. For
example, the fluorescence lifetime of tomaymycin does not
change in the presence of poly(dI-dC), which lacks the
amino group at the 2 position of the purine ring.
DISCUSSION
The fluorescence lifetime is governed by the radiative kr and
nonradiative knr rates:
T-'I= + k,. (5)
600
Hours
FIGURE 4 Kinetics of formation of tomaymycin-poly dGC adduct. Aex
= 313 fnm, Acm = 420 nm, pH 7.5, 5°C, [PI = 1 X 10-3 M, P/D = 100.
Results from global fit to three exponentials, X: = 1.11. 0, free tomay-
mycin; *, major component; A, minor component.
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TABLE 5 Kinetics of formation of tomaymycin-polynucleotide adducts
k'X106 kX 106 k1x103 k2 X 106 k2 X 103
Polynucleotide (s-l)(s- l) (M-ls- 1) (s- l) (M-ls- 1)
Poly(dG) * poly(dC) 0.5 0.5 1.0
Poly(dA-dG) - poly(dC-dT)* 11 11 44.0
Poly(dG-dT) - poly(dA-dC) 1.1 0.8 3.2 0.3 1.2
Poly(dG-dC) poly(dG-dC) 1.0 0.9 1.8 0.1 0.2
Poly(dG-dm5C) * poly(dG-dm5C) 2.3 2.1 4.2 0.2 0.4
pH 7.5, 5°C, [P] = 1 X 10-3 M, P/D = 100. Pseudo-first-order rate constant ki and bimolecular rate constant ki of lifetime component i; major component
i = 1, minor component i = 2. ki = ki[site], where each G is considered a potential bonding site.
*Results from fit to two exponentials assuming a single species of adduct.
The radiative rate of tomaymycin is not very sensitive to
environment (Barkley et al., 1986, 1991). The lifetime dif-
ferences among binding modes and bonding sites are due
largely to the nonradiative rate. Two nonradiative processes
have been shown to occur in tomaymycin: intersystem
crossing and excited-state proton transfer. The low-temper-
ature luminescence spectrum of tomaymycin ethyl ether in
an ethanol glass has two peaks (data not shown). The total
luminescence yield is 0.99 ± 0.01, and the ratio of phos-
phorescence to fluorescence quantum yields is 1.2 ± 0.2.
The radiative rate calculated from the fluorescence quantum
yield and average lifetime for calf thymus DNA adduct is
about 7 X 107 S-1 (Barkley et al., 1986). We estimate an
intersystem crossing rate for DNA adduct of about 8 X 107
s-1 by assuming a ratio of 1.2 for the intersystem crossing
and radiative rates. Excited-state proton exchange occurs at
C6 and C9 of the free drug in protic solvents (Chen et al.,
1995). In the DNA adduct, the aromatic ring of tomaymycin
is buried in the minor groove with C9 facing the floor of the
groove and C6 exposed to solvent; proton transfer from
solvent is only expected to occur at C6. Assuming that
intersystem crossing is not environmentally sensitive, the
proton transfer rate would determine the lifetime differences
in various species of DNA adduct.
The proton transfer rate depends on the proximity of
proton donors to tomaymycin in the DNA adduct. Dynam-
ical fluctuations that change the distance between tomay-
mycin and putative proton donors should result in a distri-
bution of fluorescence lifetimes. Fluorescence decay data
for calf thymus DNA adduct have been analyzed for life-
time distributions (Chen et al., 1994). At low bonding
density, the preferred lifetime model is a discrete double
exponential, arguing against fluctuational motions at the
DNA binding site. However, initial anisotropies from time-
resolved experiments of tomaymycin-DNA adducts differ
from the steady-state anisotropy of tomaymycin in ethanol
glass, suggesting that the drug may wobble with respect to
DNA.
The lifetime difference between the 1 IR and 1 IS diaste-
reomers of tomaymycin methyl ether has been attributed to
an anomeric effect on the excited-state proton transfer rate
(Chen et al., 1995). The anomeric effect may be defined as
the sensitivity of conformation and/or reactivity to the ste-
reoelectronics of substituents (Carey and Sundberg, 1990).
In tomaymycin methyl ether, for example, the antiperiplanar
overlap between the N1O-C1 1 bond and the adjacent oxygen
lone pair in the most populated conformer of the S diaste-
reomer lengthens the N1O-C1 1 bond and allows resonance
structures that enhance proton transfer at aromatic carbons,
thereby decreasing the fluorescence lifetime. The analogous
anomeric effect in DNA adduct would occur when the lone
pair on guanine N2 is antiperiplanar with the tomaymycin
N1O-CI 1 bond (Fig. 5). This torsion is prescribed by the
tomaymycin N1O-Cll guanine N2-C2 and tomaymycin
N1O-C1 1 guanine N2-H torsions. Analysis of energy mini-
mized structures of the four different binding modes in
ATGCAT adducts (Barkley et al., 1991) shows that the
anomeric effect decreases in the order R3' > R5' > S5' >
S3'. A larger anomeric effect in the R diastereomeric ad-
ducts is opposite that of the free drug and suggests that S
diastereomeric adducts have a longer lifetime than R diaste-
reomeric adducts. This is consistent with assignment of the
5.7-ns lifetime to the S3' adduct and the 2.3-ns lifetime to
the R5' adduct of ATGCAT (Cheatham et al., 1988). The
minimized structure of the S5' adduct of (Gm5C)1O gives a
smaller anomeric effect than the S3' ATGCAT adduct. If
the 7.6-ns lifetime of the Gm5C polymer adduct were as-
signed to the S5' binding mode, then the anomeric effect
could rationalize a longer lifetime in comparison to the S3'
ATGCAT adduct. The excess of protons in the minor
groove (Lamm and Pack, 1990; Hanlon and Pack, 1994)
H
N-
10
II/N CD
c1 'NHIS
H
N
IH N <D
+ / N*H
NCH
(+) W(+)
CNN (2)
H N'(D
IN / I,*
FIGURE 5 Illustration of the anomeric effect for the tomaymycin-DNA
adduct, showing the tomaymycin N10-C 1I guanine N2-C torsion.
1929Barkley et al.
Volume 70 April 1996
may be involved in proton transfer to the aromatic ring of
tomaymycin in DNA adducts.
The magnitude of the anomeric effect decreases with
increasing dielectric constant of the medium (Carey and
Sundberg, 1990). The dielectric constant of about 20 in the
DNA minor groove (Jin and Breslauer, 1988) is modulated
by the dipole moments of bases adjacent to the bonding site.
The dipole moments of guanine and cytosine are about 2-3
times larger than the dipole moments of adenine and thy-
mine (DeVoe and Tinoco, 1962), causing the dielectric
constant to be locally higher in the proximity of G or C
bases compared to A or T bases. Because the anomeric
effect decreases the fluorescence lifetime by increasing the
proton transfer rate, the lifetimes of adducts with G or C
adjacent to the modified guanine are expected to be longer.
Bonding sequences such as GGG, CGC, and m5CGm5C
have the longest lifetimes (Table 4), supporting this line of
reasoning.
The pyrrolo[1,4]benzodiazepines bond to B-DNA with
relatively minor distortion of the helix. Tomaymycin ap-
pears to perturb DNA structure more than does anthramy-
cin. The x-ray structure of anthramycin-d(CCAACGT-
TGG)2 adduct has normal minor groove width and propeller
twist, but ± 100 helical twist changes compared to uncom-
plexed decamer structures (Kopka et al., 1994). 1H and 31p
NMR studies of anthramycin-d(ATGCAT)2 adduct show
B-type sugar conformation and backbone perturbations at
the two phosphates on the 5' side of the covalently modified
guanine and the cytosine of the unmodified strand. Tomay-
mycin-d(CICGAATTCICG)2 adduct has modest perturba-
tions in sugar conformation, the most substantial of which
occurs at the covalent attachment site and its 5' nucleoside,
and in one phosphate on the 5' side of the modified guanine.
Chemical and enzymatic probes also provide evidence for
drug-induced changes in DNA conformation (Hertzberg et
al., 1986; Kizu et al., 1993). MPE-Fe(II) cleavage is en-
hanced in AT-rich regions near drug-bonding sites. Tomay-
mycin but not anthramycin alters the specificity of the
methylene blue cleavage reaction and causes additional
strand breakages three bases away from the covalently
modified guanine. Both drugs inhibit hydroxyl radical
cleavage and make a DNase I footprint, with tomaymycin
having the larger effect. Finally, both drugs induce bending
ofDNA as determined by electrophoretic analysis of ligated
oligomers containing unique drug-bonding sites (Kizu et al.,
1993). Tomaymycin bends the DNA about 110 at all five
sites tested, whereas anthramycin causes about 70 bending
at two sites and no bending at the other three sites.
These subtle DNA conformation changes are probably
responsible for the variations in saturation level with
pyrrolo[1,4]benzodiazepine and DNA sequence. Neither an-
thramycin nor tomaymycin fills all possible bonding sites
on natural or synthetic DNAs. Presumably, bonding of drug
is limited by the energetic cost of deforming the DNA.
Depending on the size taken for the bonding site, the max-
imum coverage would be one drug per 3 to 5 base pairs or
P/D = 6 to 10. Anthramycin induces less distortion and
saturates calf thymus DNA at higher binding density (PRD
= 13) than does tomaymycin (P/D = 18). Tomaymycin
saturates calf thymus DNA and homopurine sequences at
higher binding density (P/D = 18) than alternating copol-
ymer sequences (P/D = 28). This suggests that the confor-
mational changes are greater in the alternating copolymers
than in natural DNA and homopurine sequences. DNA
bending measurements, on the other hand, indicate about
the same amount of tomaymycin-induced bending at
5'AGA and 5'CGC sites (Kizu et al., 1993).
The origin of the sequence specificity of tomaymycin
remains elusive. Kizu et al. (1993) found that sequence
specificity correlated with greater DNA bending and faster
bonding kinetics for anthramycin. Table 6 summarizes the
trinucleotide sequence specificity of tomaymycin based on
UvrABC nuclease incision analysis (Pierce et al., 1993). For
tomaymycin, sequence specificity correlates with bonding
kinetics, but not with DNA bending. 5'AGA is preferred
over all possible sites by at least twofold. 5'TGT is 10-fold
less reactive, whereas 5'CGC and 5'GGG are about 20-fold
less reactive. The order of bonding kinetics for these sites on
synthetic polynucleotides is polydAG >> polydGT > poly-
dGC > polydG. Tomaymycin bonds 10-fold more slowly to
polydGT, 22-fold more slowly to polydGC, and 44-fold
more slowly to polydG compared to polydAG. The corre-
lation between sequence specificity and reaction rate is
hardly surprising. The UvrABC nuclease incision analysis
was performed on DNA samples after reacting with tomay-
mycin for 3 h at 25°C, not enough time for equilibration.
Therefore, the sequence specificity determined in the nucle-
ase incision assay is essentially a single time-point measure-
ment of the relative reaction kinetics. In the case of tomay-
mycin, there appears to be little if any correlation between
reactivity and deformability of bonding sites. The bending
TABLE 6 Relative preferences of tomaymycin for 5'NGN
bonding sites
Observed
Third base
First base A G T C
A 111 ± 54(5) 24 ± 17(6) 26 ± 19(5) 47 ± 18(8)
G 31 ±29(5) 4±4 (4) 6±6 (4) 45±23(12)
T 24 ± 21 (6) 12 ± 6 (3) 10 ± 5 (3) 44 ± 9 (8)
C 5±3 (8) 13± 10(10) 6±2 (4) 6±2 (11)
Calculated: a = 4.2, b = 2.6, y = 3.8, z = 2.6
Third Base
First base A G T C
A 105 (abyz) 40 (aby) 41 (ayz) 16 (ay)
G 28 (abz) 11 (ab) 11 (az) 4 (a)
T 25 (byz) 10 (by) 1O (yz) 4 (y)
C 7 (bz) 3 (b) 3 (z) 1 (1)
Observed data from Pierce et al. (1993). Relative intensities of UvrABC
excision bands from three DNA fragments with a total of 614 base pairs.
Numbers in parentheses are number of occurences of each bonding site.
Calculated values for model proposed in Kopka et al. (1994). Letters in
parentheses are parameters of the model as described in the text.
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angle induced by tomaymycin at 5'AGA and 5'CGC sites is
the same (Kizu et al., 1993), despite a 20-fold difference in
reactivity. Saturation level is another measure of DNA
deformation. The saturation levels of the homopurine se-
quences polydG and polydAG are the same, but the reac-
tivity differs over 40-fold.
Kopka et al. (1994) proposed a model for the sequence
specificity of anthramycin based on the x-ray structure of
anthramycin-d(CCAACGTTGG)2 adduct. This model tests
the importance of purine-purine steps and AT base pairs in
specificity. For each 5'NGN trinucleotide, a four-factor
product is constructed. Factors a and b weight the impor-
tance of 5'NG or GN3' being a purine-purine step, and
factors y and z weight the importance of 5'N or N3' being
A-T base pairs. The importance of each parameter is gauged
by how much greater it is than 1. The four parameters were
fitted to the sequence specificity data of Pierce et al. (1993)
by minimizing the sum of squares of residuals over all 16
entries. The error sum has a global minimum at a = 4.2, b
= 2.6, y = 3.8, and z = 2.6, yielding the calculated
sequence preferences given in Table 6. This analysis sug-
gests that tomaymycin favors purine steps and A-T base
pairs on the 5' side of the guanine bonding site relative to
the 3' side. Futhermore, purine steps are slightly more
favored than A-T base pairs on the 5' side but equally
favored on the 3' side. However, this model misses the
strong preference for C on the 3' side.
The preference of tomaymycin for purine-purine steps or
A-T base pairs may be explained as follows. The absence of
a 2-NH2 group on adenine makes the minor groove signif-
icantly deeper and better able to accommodate the drug
molecule, whereas guanine 2-NH2 groups push the drug
away from the floor of the groove. For guanine-binding
drugs such as the pyrrolo[1,4]benzodiazepines, ANT base
pairs adjacent to the bonding site allow more room for the
head or tail of the drug and may account for the preference
for an AGA bonding site. Purine-purine steps exhibit low
helical twist angles (Yanagi et al., 1991). The normals
between the five- and six-membered rings of tomaymycin
make a 90 angle (Arora, 1981) in comparison to a 35.4°
angle between normals in anthramycin (Mostad et al., 1978;
Arora, 1979). For anthramycin, the small helical twist pro-
vided by purine-purine steps is always more important than
the room provided by A-T base pairs adjacent to the binding
site, even though the acrylamide tail in anthramycin is
longer than the ethylidene tail in tomaymycin. In the minor
groove, the position and type of hydrogen bonds do not
change if base pairs are flipped, as in T-A and A-T. Thus if
hydrogen bonding patterns were important in drug specific-
ity, then TGT and AGA sites would be equally preferred.
This is clearly not the case, as AGA sites are 10-fold more
reactive than TGT sites. Nevertheless, as suggested by
molecular modeling studies of tomaymycin-d(ATGCAT)2
adducts, different binding modes may have different hydro-
gen bonding patterns between tomaymycin and DNA bases
or water molecules in the minor groove, which may promote
or deter the formation of certain adducts (Cheatham et al.,
1988; Barkley et al., 1991).
We thank Dr. W. A. Remers for the coordinates of energy minimized
structures of tomaymycin-DNA adducts.
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